SCHEMBL5316728

SCHEMBL5316728

O=C1NC(=O)c2c1cnc1ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 4/20 0.51
CCND1 P24385 4/20 0.51
GSK3B P49841 1/20 0.43
PARP1 P09874 5/20 0.42
PDPK1 O15530 1/20 0.42
CA12 O43570 1/20 0.42
ALOX15 P16050 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CA9 Q16790 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
KDM4E B2RXH2 1/20 0.41
GPR3 P46089 1/20 0.41
HDAC6 Q9UBN7 1/20 0.40
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
CDK5 Q00535 2/20 0.39
CDK5R1 Q15078 2/20 0.39
CASP7 P55210 2/20 0.39
PRKD3 O94806 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30433945 1.00 CDK4 (0.51) CDK4CCND1GSK3BPARP1PDPK1
SCHEMBL29973094 0.74 SMN1; SMN2 (0.44) CDK4CCND1PARP1PDPK1CA12
SCHEMBL28626976 0.74 SMN1; SMN2 (0.44) CDK4CCND1PARP1PDPK1CA12
SCHEMBL27215626 0.74 CASP3 (0.41) CDK4CCND1PARP1PDPK1CA12
SCHEMBL459050 0.73 KMT2A (0.44) PARP1PDPK1CA12ALOX15SMN1; SMN2
SCHEMBL1103721 0.73 MEN1 (0.44) PARP1PDPK1CA12ALOX15SMN1; SMN2
SCHEMBL16895263 0.73 DNMT1 (0.46) SMN1; SMN2KDM4EGPR3MEN1MAPT
SCHEMBL29641696 0.73 KMT2A (0.44) PARP1PDPK1CA12ALOX15SMN1; SMN2
SCHEMBL8874682 0.73 KDM4E (0.42) CDK4CCND1PARP1PDPK1CA12
SCHEMBL5469529 0.72 NPC1 (0.48) GSK3BSMN1; SMN2KDM4EMAPTCAMK2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112358479-B Synthesis method of pyrrolo [3,4-c ] quinoline-1, 3-dione compound 西北师范大学 2023-06-16 CN claimed
CN-112358479-B Synthesis method of pyrrolo [3,4-c ] quinoline-1, 3-dione compound 西北师范大学 2023-06-16 CN disclosed
CN-112358479-B Synthesis method of pyrrolo [3,4-c ] quinoline-1, 3-dione compound 西北师范大学 2023-06-16 CN disclosed
CN-112358479-A Synthesis method of pyrrolo [3,4-c ] quinoline-1, 3-diketone compound 西北师范大学 2021-02-12 CN disclosed
CN-103172587-A Benzisothiazole-3-ketone-2-amide compound with Caspase-3 inhibiting activity TIANJIN INT JOINT ACADEMY BIOTECHNOLOGY & MEDICINE 2013-06-26 CN disclosed
CN-103169700-A Application of 1,2-benzisothiazole-3-ketone compound in inhibiting caspase-3 activity TIANJIN INT JOINT ACADEMY BIOTECHNOLOGY & MEDICINE 2013-06-26 CN disclosed
US-20070191337-A1 Annellated carbamyl-aza-heterocyclic compounds, a focused library, pharmaceutical compositions, and methods of preparing the same IVASHCHENKO ALEXANDER 2007-08-16 US disclosed
EP-1746100-A1 ANNELATED CARBAMOYLASE-HETEROCYCLES, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE PRODUCTION THEREOF "Chemical diversity Research Institute", Ltd. (RU) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191337-A1 Annellated carbamyl-aza-heterocyclic compounds, a focused library, pharmaceutical compositions, and methods of preparing the same ADORA2A, CDK20, CDK2 CDK4 14/4885CCND1 23/4885GSK3B 4546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.